1. Academic Validation
  2. Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission

Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission

  • Sci Adv. 2024 Dec 6;10(49):eadq1383. doi: 10.1126/sciadv.adq1383.
Paula-Josefina Gomez-Gonzalez 1 Antima Gupta 1 Laura G Drought 1 Avnish Patel 1 John Okombo 2 3 Mariëtte van der Watt 4 Ryan Walker-Gray 1 Kyra A Schindler 2 3 Anna Y Burkhard 2 3 Tomas Yeo 2 3 Sunil K Narwal 2 3 Talia S Bloxham 3 5 Christian Flueck 1 Eloise M Walker 1 Joshua A Rey 1 Kate J Fairhurst 2 3 Janette Reader 4 6 Heekuk Park 3 5 Harry G Pollard 1 Lindsay B Stewart 1 Luke Brandner-Garrod 1 Mojca Kristan 1 Geert-Jan Sterk 7 Youri M van Nuland 8 Emilia Manko 1 Donelly A van Schalkwyk 1 Yang Zheng 7 Rob Leurs 7 Koen J Dechering 8 Anna Caroline C Aguiar 9 Rafael V C Guido 10 Dhelio B Pereira 11 Patrick K Tumwebaze 12 Samuel L Nosbya 12 Philip J Rosenthal 13 Roland A Cooper 14 Mike Palmer 15 Tanya Parkinson 15 Jeremy N Burrows 16 17 Anne-Catrin Uhlemann 3 5 Lyn-Marié Birkholtz 4 6 Jennifer L Small-Saunders 3 5 James Duffy 16 David A Fidock 2 3 5 Alan Brown 15 Mark Gardner 15 David A Baker 1
Affiliations

Affiliations

  • 1 Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
  • 2 Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA.
  • 3 Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Irving Medical Center, New York, NY, USA.
  • 4 Department of Biochemistry, Genetics and Microbiology, University of Pretoria, Pretoria, South Africa.
  • 5 Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
  • 6 Institute for Sustainable Malaria Control, University of Pretoria, Pretoria, South Africa.
  • 7 Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • 8 TropIQ Health Sciences, Nijmegen, Netherlands.
  • 9 Federal University of São Paulo, São Paulo, Brazil.
  • 10 Sao Carlos Institute of Physics, University of São Paulo, São Carlos, Brazil.
  • 11 Research Center for Tropical Medicine of Rondonia, Porto Velho, Brazil.
  • 12 Infectious Diseases Research Collaboration, Kampala, Uganda.
  • 13 University of California, San Francisco, CA, USA.
  • 14 Dominican University of California, San Rafael, CA, USA.
  • 15 Salvensis, Sandwich, UK.
  • 16 Medicines for Malaria Venture, Geneva, Switzerland.
  • 17 Liverpool School of Tropical Medicine, Liverpool, UK.
Abstract

Cyclic nucleotide-dependent phosphodiesterases (PDEs) play essential roles in regulating the malaria Parasite life cycle, suggesting that they may be promising antimalarial drug targets. PDE inhibitors are used safely to treat a range of noninfectious human disorders. Here, we report three subseries of fast-acting and potent Plasmodium falciparum PDEβ inhibitors that block asexual blood-stage Parasite development and that are also active against human clinical isolates. Two of the inhibitor subseries also have potent transmission-blocking activity by targeting PDEs expressed during sexual Parasite development. In vitro drug selection experiments generated parasites with moderately reduced susceptibility to the inhibitors. Whole-genome Sequencing of these parasites detected no mutations in PDEβ but rather mutations in downstream effectors: either the catalytic or regulatory subunits of cyclic adenosine monophosphate-dependent protein kinase (PKA) or in the 3-phosphoinositide-dependent protein kinase that is required for PKA activation. Several properties of these P. falciparum PDE inhibitor series make them attractive for further progression through the antimalarial drug discovery pipeline.

Figures
Products